Loading...
XASEELMD
Market cap242mUSD
Dec 23, Last price  
28.65USD
1D
3.32%
1Q
39.28%
Jan 2017
638.40%
IPO
653.95%
Name

Electromed Inc

Chart & Performance

D1W1MN
XASE:ELMD chart
P/E
47.05
P/S
4.43
EPS
0.61
Div Yield, %
0.00%
Shrs. gr., 5y
0.53%
Rev. gr., 5y
11.82%
Revenues
55m
+13.83%
8,752,12912,998,62714,303,84819,003,50719,524,48915,104,42215,487,87519,408,38522,991,99925,861,14428,697,62231,299,75032,470,68835,756,00041,659,00048,067,00054,716,000
Net income
5m
+62.67%
267,8521,332,906916,3381,055,577186,606-1,329,276-1,288,5941,092,4862,212,5022,229,4721,902,3961,969,2184,161,0002,362,0002,305,0003,166,0005,150,000
CFO
9m
+589.51%
243,158-1,157,706607,937-1,415,104-1,171,7771,876,6572,062,6612,781,2142,166,9031,191,1212,442,2002,589,8744,196,4483,077,000-686,0001,315,0009,067,000
Earnings
Feb 11, 2025

Profile

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.
URL
https://smartvest.com/
IPO date
Aug 13, 2010
Employees
170
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
54,716
13.83%
48,067
15.38%
41,659
16.51%
Cost of revenue
48,135
12,464
11,573
Unusual Expense (Income)
NOPBT
6,581
35,603
30,086
NOPBT Margin
12.03%
74.07%
72.22%
Operating Taxes
1,886
920
692
Tax Rate
28.66%
2.58%
2.30%
NOPAT
4,695
34,683
29,394
Net income
5,150
62.67%
3,166
37.35%
2,305
-2.41%
Dividends
Dividend yield
Proceeds from repurchase of equity
(275)
(153)
(1,448)
BB yield
0.21%
0.16%
1.71%
Debt
Debt current
Long-term debt
7
162
82
Deferred revenue
(86)
Other long-term liabilities
12
5
Net debt
(16,073)
(7,210)
111,929
Cash flow
Cash from operating activities
9,067
1,315
(686)
CAPEX
(395)
(1,716)
(1,525)
Cash from investing activities
(395)
(1,716)
(1,525)
Cash from financing activities
36
(380)
(1,525)
FCF
7,200
30,443
24,086
Balance
Cash
16,080
7,372
8,153
Long term investments
(120,000)
Excess cash
13,344
4,969
Stockholders' equity
23,755
18,879
15,865
Invested Capital
31,213
32,224
34,163
ROIC
14.80%
104.49%
104.30%
ROCE
14.77%
94.11%
88.07%
EV
Common stock shares outstanding
8,865
8,701
8,769
Price
15.03
40.34%
10.71
11.10%
9.64
-14.61%
Market cap
133,235
42.98%
93,186
10.24%
84,530
-15.99%
EV
117,162
85,976
196,459
EBITDA
7,422
36,216
30,714
EV/EBITDA
15.79
2.37
6.40
Interest
25
Interest/NOPBT
0.08%